Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Anti-Inflammatory Therapeutics Market Value Growth And Long-Term Outlook
The anti-inflammatory therapeutics market has experienced consistent expansion in its size over recent years. It is projected to expand from $117.28 billion in 2025 to $122.27 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.3%. This historical growth can be attributed to factors such as the increasing prevalence of arthritis, a rise in inflammatory bowel disease cases, the expansion of hospital pharmacy networks, the adoption of corticosteroids, and the demand for pain management drugs.
The anti-inflammatory therapeutics market size is projected to experience robust expansion in the coming years. This market is predicted to reach a valuation of $152.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This anticipated growth is attributable to factors such as the advancement of targeted biologics, the incorporation of artificial intelligence in drug discovery, the proliferation of online pharmacies, the expanding elderly population, and a heightened emphasis on personalized medicine. Key trends anticipated during this period encompass tailored anti-inflammatory treatments, a greater adoption of biologic medications, the development of minimally invasive drug delivery methods, an increase in chronic pain management solutions, and a wider reach for online pharmacy distribution.
Get A Free Sample Report With In-Depth Market Insights:
Anti-Inflammatory Therapeutics Market Growth Factors Behind Sustained Expansion
The expanding occurrence of inflammatory bowel disease is anticipated to boost the growth of the anti-inflammatory therapeutics market moving forward. Inflammatory bowel disease (IBD) is a persistent ailment that causes inflammation of the gastrointestinal tract. Anti-inflammatory therapeutics are essential in addressing Crohn’s disease by mitigating inflammation, managing its symptoms, and reducing the necessity for surgery. For example, in June 2023, Crohn’s and Colitis Canada, a non-profit organization based in Canada, reported that 470,000 individuals in Canada are projected to suffer from inflammatory bowel disease (IBD) by 2035, an increase from an estimated 322,600 in 2023. Thus, the rising prevalence of inflammatory bowel disease is propelling the expansion of the anti-inflammatory therapeutics market.
Anti-Inflammatory Therapeutics Market Breakdown By Product Type And Application
The anti-inflammatory therapeutics market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Anti-Inflammatory Biologics
2) By Indication: Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases, Other Inflammatory Diseases
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Aspirin, Naproxen, Diclofenac, Celecoxib, Indomethacin, Ketoprofen
2) By Corticosteroids: Prednisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone
3) By Anti-Inflammatory Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Monoclonal Antibodies, Recombinant Proteins, Fusion Proteins
Anti-Inflammatory Therapeutics Market Industry Trends Fueling Future Revenue Growth
Leading firms in the anti-inflammatory therapeutics market are concentrating on creating cutting-edge biologic treatments to enhance patient results for those suffering from chronic inflammatory ailments. Such sophisticated treatments aim to provide precise immune regulation, improved effectiveness, and superior tolerability when contrasted with traditional options like corticosteroids. As an example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, and Sanofi, a France-based pharmaceutical and healthcare company, introduced Kevzara (sarilumab). This product is notable as the inaugural and sole anti-inflammatory biologic advised for adult patients diagnosed with polymyalgia rheumatica (PMR) who either show insufficient response to corticosteroids or cannot endure corticosteroid dosage reduction. This innovative IL-6 receptor inhibitor presents a more potent and corticosteroid-reducing treatment alternative, thereby addressing a considerable gap in PMR management and bolstering the standing of these companies within the anti-inflammatory therapeutics market.
Anti-Inflammatory Therapeutics Market Company Landscape And Competitive Strategy
Major companies operating in the anti-inflammatory therapeutics market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Co. Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.
View The Full Anti-Inflammatory Therapeutics Market Report:
Anti-Inflammatory Therapeutics Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the anti-inflammatory therapeutics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
